– Bloomberg
Morgan Stanley Maintains Equal-Weight on UDR, Lowers Price Target to $47
Morgan Stanley analyst Richard Hill maintains UDR (NYSE:UDR) with a Equal-Weight and lowers the price target from $51 to $47.
Related Posts
Fear & Greed Index Moves To ‘Neutral’ Zone Following Jobs Data
The CNN Money Fear and Greed index moved to the "Neutral" zone after US stocks recorded sharp gains on Friday.
Mizuho Upgrades Biogen to Buy, Raises Price Target to $270
Mizuho analyst Salim Syed upgrades Biogen (NASDAQ:BIIB) from Neutral to Buy and raises the price target from $207 to $270.
Veterans With ALS Who Support Co’s Request For The FDA To Hold A Public Advisory Committee Meeting To Engage In Scientific Discourse About The “Clinically Meaningful” Evidence Supporting FDA’s Approval Of A Mesenchymal Stem Cell Therapy, NurOwn
Veterans have a Significantly Increased Risk of 100% Fatal ALS, Caused by their Service for our Country
FDA Advisory Committee Meeting is Essential to Allow Veterans' Voices to be Heard about Need for